View our list of available Coronavirus (COVID-19, SARS-CoV-2, 2019-nCOV) antibodies, recombinant proteins, ELISA Kits... Options Full Datasheet Printer Friendly Datasheet Prepare for Printing Full Datasheet Printer Friendly Datasheet Prepare for Printing Have Questions? Ask Us! Request A Quote Today! Add To Compare List PI-103, inhibitor Catalog # MBS8506504 Unit / Price 5 mg / $300 +1 FREE 8GB USB 5x5 mg / $1,160 +1 FREE 8GB USB Product Name Product Info Accession #s Product Desc Diseases/Tissues/Pathways Applications References Product Name PI-103, Inhibitor Full Product Name PI-103 Product Gene Name PI-103, inhibitor[Similar Products] Research Use Only For Research Use Only. Not for use in diagnostic procedures. TOP Purity/Purification >99% Solubility DMSO >=24mg/mL - Water <1mg/mL - Ethanol <1mg/mL Formula C19H16N4O3 CAS Number 371935-74-9 Preparation and Storage Store at-20 degree C 2 years. ISO Certification Manufactured in an ISO 9001:2015 Certified Laboratory. Other Notes Small volumes of PI-103, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply. TOP Related Product Information for PI-103, inhibitor PI-103 is a potent, cell-permeable, ATP-competitive PI3K family members inhibitor with IC50 of 2, 8, 20, 26, 48, 83, 88, 150 nM for DNA-PK, p110alpha, mTORC1, PI3-KC2beta, p110delta, mTORC2, p110beta, and p110 gamma, respectively. It shows little activity against a wide array of protein kinases at 10 mM. It blocks glioma proliferation by blocking the PI 3-K/Akt pathway in vitro and in vivo. PI-103 was essentially cytostatic for cell lines and induced cell cycle arrest in the G1 phase. In blast cells, PI-103 inhibited leukemic proliferation, the clonogenicity of leukemic progenitors and induced mitochondrial apoptosis, especially in the compartment containing leukemic stem cells. PI-103 had additive proapoptotic effects with etoposide in blast cells and in immature leukemic cells. [1][2][3] Product Categories/Family for PI-103, inhibitor Stem Cells; Cancer; Cardiovascular; Cell Biology; Epigenetics & Nuclear Signaling; Developmental Biologys; Immunology; Drug Discovery Products; Metabolism; Neuroscience; Signal Transduction Testing Data of PI-103, inhibitor PI-103 is a potent, cell-permeable, ATP-competitive PI3K family members inhibitor with IC50 of 2, 8, 20, 26, 48, 83, 88, 150 nM for DNA-PK, p110alpha, mTORC1, PI3-KC2beta, p110delta, mTORC2, p110beta, and p110gamma, respectively. It shows little activity against a wide array of protein kinases at 10 mM. It blocks glioma proliferation by blocking the PI 3-K/Akt pathway in vitro and in vivo. PI-103 was essentially cytostatic for cell lines and induced cell cycle arrest in the G1 phase. In blast cells, PI-103 inhibited leukemic proliferation, the clonogenicity of leukemic progenitors and induced mitochondrial apoptosis, especially in the compartment containing leukemic stem cells. PI-103 had additive proapoptotic effects with etoposide in blast cells and in immature leukemic cells. [1][2][3] TOP Molecular Weight 348.36 TOP Precautions All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines. Disclaimer While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information. TOP